Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 2/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | DPP4 | P27487 | 3/20 | 0.35 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.35 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9918326 | 0.89 | MEN1 (0.46) | MEN1KMT2ASMN1; SMN2GAAMAPT | |
| SCHEMBL9918307 | 0.89 | MEN1 (0.46) | MEN1KMT2ASMN1; SMN2GAAMAPT | |
| SCHEMBL12125453 | 0.88 | KMT2A (0.56) | MEN1KMT2ASMN1; SMN2GAAMAPT | |
| SCHEMBL23338576 | 0.85 | MEN1 (0.36) | MEN1KMT2ASMN1; SMN2GAAMAPT | |
| SCHEMBL20232928 | 0.84 | GAA (0.38) | MEN1KMT2ASMN1; SMN2GAAMAPT | |
| SCHEMBL19735105 | 0.84 | KMT2A (0.42) | MEN1KMT2ASMN1; SMN2GAAMAPT | |
| SCHEMBL12384620 | 0.80 | GAA (0.38) | MEN1KMT2ASMN1; SMN2GAAMAPT | |
| SCHEMBL13035374 | 0.80 | CPN1 (0.38) | MEN1KMT2AGAAALDH1A1DPP4 | |
| SCHEMBL679537 | 0.80 | PIK3CD (0.38) | MEN1KMT2AALDH1A1DPP4DPP8 | |
| SCHEMBL15837591 | 0.80 | PIK3CD (0.38) | MEN1KMT2AALDH1A1DPP4DPP8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023172737-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | KUMQUAT BIOSCIENCES INC. (US) | 2023-09-14 | — | — | WO | disclosed |
| US-20230133671-A1 | SETD2 INHIBITORS AND RELATED METHODS AND USES, INCLUDING COMBINATION THERAPIES | Epizyme, Inc. (US) | 2023-05-04 | — | — | US | disclosed |
| WO-2023015559-A1 | MACROCYCLE COMPOUNDS AS INHIBITORS OF RAS | NUTSHELL BIOTECH (SHANGHAI) CO., LTD. (CN) | 2023-02-16 | — | — | WO | disclosed |
| WO-2022159818-A1 | POLY(ADP-RIBOSE) GLYCOHYDROLASE (PARG) INHIBITORS AGAINST COVID MACRODOMAIN AND METHODS OF USING THE SAME | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2022-07-28 | — | — | WO | disclosed |
| WO-2020037079-A1 | SUBSTITUTED INDOLES AND METHODS OF USE THEREOF | Epizyme, Inc. (US) | 2020-02-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230133671-A1 | SETD2 INHIBITORS AND RELATED METHODS AND USES, INCLUDING COMBINATION THERAPIES | EZH2, HDAC2, SETD2 | MEN1 2641/4885KMT2A 52/4885SMN1; SMN2 2240/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.